Administered five to six months after the second booster, in persons over 65, immunosuppressed persons over 65, immunosuppressed persons, chronically ill persons and health care workers with chronic diseases. Preferably, administer the SARS-CoV-2 messenger RNA-based platform vaccine.

Maintain homologous schedules using the vaccines authorized for the different age groups (Sinopharm 3 and 4 years, Pfizer 5 to 11 years); Administer an additional dose in cases of immunocompromised hosts using the same vaccine as the one used previously; Wait for further evidence before recommend

The immunization technical standard is in the process of being updated; Evidence and epidemiological data are being compiled to determine the inclusion of the Hepatitis A and meningococcal vaccine.